LIQUID BIOPSY FOR T790M DETECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN A PUBLIC HOSPITAL IN CORRIENTES CAPITAL

LORENZINI CAMPOS, M. N.; ZIMMERMANN, M.C.; ACEVEDO, R. M.; SUSSINI, M. M.; LORENZINI CAMPOS, M. N.; ZIMMERMANN, M.C.; ACEVEDO, R. M.; SUSSINI, M. M.

Mar del Plata

Congreso; Congreso anual de la Asociación Argentina de Farmacología Experimental; 2019

Sociedad Argentina de Farmacología Experimental

Access limitations to an early diagnosisinfluences high rates of lung cancer mortality in the northeastregion of Argentina. Lack of specialists and equipment plus longdistances to medical centers that perform such studies are someof the reasons. Non-small cell lung cancer (NSCLC) constitutes85% of all lung cancer cases and shows the highest mortality.Solid biopsy has been demonstrated to be unsafe for the patientand has low sensitivity to detect tumor dynamics, drugsensitivity and residual lesions. In addition, treatment hasevolved into customized strategies based on histological andmolecular subtypes. Due to T790M mutation in the EGFR gene isactionable, the objective of the present study was to optimize itsdetection in NSCLC by liquid biopsy in patients of the UniversityHospital in Corrientes. To this purpose, an observational crosssectional study was performed in patients at any stage of NSCLCwho attended to the pneumonology service between June 2018and July 2019. Circulating DNA extraction was carried out usingQIAmp® MinElute® ccfDNA kit. T790M was evaluated byperforming AS-PCR and 2% agarose electrophoresis. As a result,positive control was amplified however none of the patientscarried the mutation. Thus, it was possible to develop a methodfor T790M detection in Corrientes, which will be accessible topatients in the region.